VolitionRx Limited (NYSE American: VNRX) released a corporate update detailing recent clinical and commercial advancements across its diagnostics portfolio. The company announced the submission of a feline lymphoma manuscript that could trigger a potential $5 million milestone payment, underscoring its commitment to veterinary diagnostics. Additionally, VolitionRx noted continued momentum in licensing discussions with more than a dozen global diagnostic and liquid biopsy companies, reflecting growing interest in its epigenetic technology.
The update also highlighted progress in the company's diagnostic pipeline. VolitionRx reported validation advancements for its Capture-Seq cancer detection platform, which aims to improve early cancer detection through blood-based tests. The company's Nu.Q NETs program, focused on sepsis and other NETosis-associated diseases, is also expanding, with ongoing studies to validate its clinical utility. In Europe, VolitionRx is pursuing reimbursement in France for its lung cancer assay, a critical step toward routine clinical use.
VolitionRx is a multinational company dedicated to advancing epigenetics for early disease detection and monitoring. Its subsidiaries develop simple, cost-effective blood tests for cancers and diseases like sepsis. The company's research is centered in Belgium, with additional offices in the U.S. and London. For more information, visit the company's website at https://volition.com/.
The full press release is available at https://ibn.fm/nX9FK. This update reflects VolitionRx's strategic focus on commercializing its epigenetic-based diagnostics and securing partnerships to expand its reach.
